For example, Cet (anti-EGFR mAb) is used for the treatment of colorectal cancer [51] and head and neck cancer [52], panitumumab (anti-EGFR mAb) has been approved for colorectal cancer [51], and necitumumab (anti-EGFR mAb) is used to treat squamous cell carcinoma of the lung [53]. This evidence concerns the gene EGFR and head and neck cancer.